FINWIRES · TerminalLIVE
FINWIRES

Heron Neutron Gets Taiwan Approval for Phase I/II Trial of B10 L-BPA Injection; Shares Up 8%

By

Heron Neutron Medical Corp (TPE:7799) said its B10 L-BPA injection received approval from the Taiwan Food and Drug Administration, Ministry of Health and Welfare, for Phase I/II investigator-initiated clinical trials of cancer treatment, according to a Wednesday filing to the Taiwan stock exchange.

With this approval, the company will initiate Phase I and Phase II investigator-initiated human clinical trials of B10 L-BPA injection as neoadjuvant therapy for locally advanced oral cancer.

Investigator-initiated trials are primarily conducted for scientific or medical research purposes and are generally initiated and led by medical institutions, academic institutions, or investigators. The company primarily acts as the sponsor, providing resources and support for such academic research, Heron said.

The company's shares were up nearly 8% in recent trade.

Related Articles

Asia

Coles Group Appeals ACCC's Rejection of Kalgoorlie Site Acquisition

Coles Group (ASX:COL) lodged an appeal against the Australian Competition and Consumer Commission's (ACCC) decision to block its proposed purchase of a supermarket and liquor site in Kalgoorlie, Western Australia, according to a Wednesday filing with the Australian Competition Tribunal.Following a phase two review, the ACCC said the acquisition might materially harm competition in the retail groceries space and likely lead to the exit of an independent full-line competitor from Kalgoorlie.In its appeal, Coles said the regulator's decision was not "objectively correct or preferable."The company's shares were down nearly 1% in recent Thursday trade.

ASX:COL
Asia

Unisplendour to Dilute Stake in Computer Unit to 29.4%; Shares Up 9%

Semiconductor company Unisplendour (SHE:000938) said it will dilute its stake in subsidiary Unisplendour Computer Technology amid a 440-million-yuan capital increase.Unisplendour will waive its pre-emptive subscription rights, reducing its stake to 29.42% from 51%, with the subsidiary exiting consolidation, according to a Thursday filing with the Shenzhen bourse.One of the five investors of the capital increase, Haichen Huicai, will acquire a 12% stake in Unisplendour Computer Technology from five existing shareholders before the implementation of the capital increase.Shares of Unisplendour jumped 9% in recent trade.

SHE:000938
Asia

WW Holdings Unit Injects $2 Million Into Cambodian Stepdown Subsidiary

WW Holdings' (TPE:8442) subsidiary, Global Worth Investment, will increase the capital of its unit, TWT Leather (Cambodia), by $2 million, bringing its total investment to $5 million, according to a Wednesday Taiwan bourse filing.The investment will be made in phases and funded through the company's funds and financial institutions.The capital increase is aimed at strengthening the unit's operating scale and expanding its production base.

TPE:8442